Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 1
1969 3
1970 3
1971 2
1973 3
1974 1
1975 3
1976 3
1977 4
1978 3
1979 7
1980 13
1981 6
1982 4
1983 5
1984 11
1985 15
1986 11
1987 13
1988 18
1989 13
1990 9
1991 11
1992 10
1993 18
1994 12
1995 9
1996 9
1997 9
1998 11
1999 15
2000 15
2001 11
2002 13
2003 18
2004 25
2005 31
2006 35
2007 36
2008 63
2009 70
2010 57
2011 88
2012 101
2013 104
2014 114
2015 140
2016 164
2017 194
2018 241
2019 265
2020 357
2021 463
2022 530
2023 557
2024 674
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,184 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Among authors: al ali hk. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL, Ali HJ, Koutroumpakis E, Ganatra S, Deswal A. Palaskas NL, et al. Among authors: ali hj. BMJ. 2024 May 15;385:e075859. doi: 10.1136/bmj-2023-075859. BMJ. 2024. PMID: 38749554 Review.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Al-Ali HK, et al. Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4. Br J Haematol. 2020. PMID: 32017044 Free article. Clinical Trial.
Epigenetic regulation of tumor immunity.
Pang L, Zhou F, Liu Y, Ali H, Khan F, Heimberger AB, Chen P. Pang L, et al. Among authors: ali h. J Clin Invest. 2024 Jun 17;134(12):e178540. doi: 10.1172/JCI178540. J Clin Invest. 2024. PMID: 39133578 Free PMC article. Review.
4,184 results